| In silico design | Stable molecule | Formulation development | Market launch |
|---|
| FGF2 for cultivation media | FGF2-STAB® (patent WO2017089016A1) |
Global distribution agreement Global license agreement |
| FGF2 for cosmetics | FGF2-STAB® (patent WO2017089016A1) |
| FGF2 for veterinary medicine | FGF2-STAB® (patent WO2017089016A1) |
| FGF2 for wound healing | FGF2-STAB® (patent WO2017089016A1) |
| Other FGFs for cultivation media | FGFx-STAB (8 molecules in the pipeline) |
| Other FGFs for medical use (osteoarthritis, lung injury, obesity and diabetes) | FGFx-STAB (3 molecules) |
| Other FGFs for medical use (neurodegenerative disease, angina pectoris) | FGFx (2 molecules) |
Our molecules are being developed with a support of:
